It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The survival of modern medicine depends heavily on the effective prevention and treatment of bacterial infections, are threatened by antibacterial resistance. The increasing use of antibiotics and lack of stewardship have led to an increase in antibiotic-resistant pathogens, so the growing issue of resistance can be resolved by emphasizing chemically synthesized antibiotics. This study discovered SMJ-2, a synthetic indole derivative, is effective against all multidrug-resistant gram-positive bacteria. SMJ-2 has multiple targets of action, but the primary mechanism inhibits respiratory metabolism and membrane potential disruption. SMJ-2 was discovered to interfere with the mevalonate pathway, ultimately preventing the synthesis of farnesyl diphosphate, a precursor to the antioxidant staphyloxanthin, eventually releasing reactive oxygen species, and leading phagocytic cells to destroy pathogens. Additionally, no discernible biochemical and histopathological alterations were found in the mouse acute toxicity model. This study emphasizes mechanistic insights into SMJ-2 as a potential antibacterial with an unusual method of action.
Synthetic indole derivative kills gram-positive bacteria by quenching the respiratory metabolism pathway.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 CSIR- Institute of Microbial Technology, Sector 39-A, Clinical Microbiology & Antimicrobial Research Laboratory, Chandigarh, India (GRID:grid.417641.1) (ISNI:0000 0004 0504 3165); Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India (GRID:grid.469887.c) (ISNI:0000 0004 7744 2771)
2 National Institute of Pharmaceutical Education and Research Mohali, Department of Natural Products, Mohali, India (GRID:grid.419631.8) (ISNI:0000 0000 8877 852X)
3 CSIR- Institute of Microbial Technology, Sector 39-A, Clinical Microbiology & Antimicrobial Research Laboratory, Chandigarh, India (GRID:grid.417641.1) (ISNI:0000 0004 0504 3165); University of Oklahoma, Department of Chemistry and Biochemistry, Norman, USA (GRID:grid.266900.b) (ISNI:0000 0004 0447 0018)